Brief: Vaxart Reports Positive Clinical Data Demonstrating Second-Generation Vaccine Technology Produces Stronger Antibody Responses Than First-Generation
11/06/2025 12:47
June 11 (Reuters) - Vaxart Inc VXRT.O: VAXART REPORTS POSITIVE CLINICAL DATA DEMONSTRATING THAT ITS SECOND-GENERATION VACCINE TECHNOLOGY PRODUCES MUCH STRONGER ANTIBODY RESPONSES THAN ITS FIRST-GENERATION TECHNOLOGY VAXART INC: VACCINE CANDIDATES WERE SAFE AND WELL-TOLERATED ACROSS ALL DOSE GROUPS WITH NO VACCINE-RELATED SERIOUS ADVERSE EVENTS REPORTED VAXART INC - VACCINE CANDIDATES SAFE AND WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS VAXART INC - PHASE 3 TRIAL COULD BEGIN AS EARLY AS 2026 VAXART: SECOND-GENERATION NOROVIRUS CONSTRUCTS PRODUCE STATISTICALLY SIGNIFICANT RISES IN GI.1 & GII.4 BLOCKING ANTIBODIES VERSUS FIRST-GENERATION Source text: ID:nGNXyM9gf Further company coverage: VXRT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaxart
See all newsBrief: Vaxart Expands Intellectual Property Portfolio With European Patent Protecting Proprietary Norovirus Vaccine Technology
Vaxart Q2 revenue falls on lower government contract income
Brief: Vaxart Q2 Net Income USD -13.494 Million
Brief: Vaxart Enters Cooperation Agreement With Stockholder Group And Announces Board And Corporate Governance Enhancements
Vaxart Q1 revenue more than doubles on government contracts